Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

Sickle Cell Disease clinical trials near you

A clinical trial is a research study that tests whether a treatment is safe and works. Taking part is always your choice, and you can stop at any time. Listing a study here is not a recommendation — talk it through with your own team.

138 recruiting studiesFrom ClinicalTrials.gov (opens in a new tab)

Trial results

8 shown of 138

8 shown of 138 clinical trials.

  1. RecruitingPhase 2InterventionalNCT05640271

    Tocilizumab for Acute Chest Syndrome

    Sickle Cell Disease, Acute Chest Syndrome

    The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigators are hopeful that this will be an effective strategy. The investigators will be looking at how a low dose of tocilizumab affects oxygen status, clinical outcomes, and laboratory markers in patients admitted to the hospital with acute chest syndrome.

    Sites
    1
    Target
    200
    Study sites
    Chicago, US

    Sponsor: University of Chicago

    View on ClinicalTrials.gov(opens in a new tab)
  2. RecruitingInterventionalNCT07090668

    Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

    Sickle Cell Disease

    The goal of this study is to evaluate the effects of transauricular vagus and trigeminal nerve stimulation on the treatment of pain in children with Sickle Cell Disease. * The primary objective is to determine the feasibility of using a tAN device to treat pain in pediatric participants with SCD by assessing the completion rate, stimulation tolerability, and acceptability of the intervention measures. * The secondary objective is to assess the preliminary efficacy of using a tAN device as a remedy for pain in pediatric SCD subjects by analyzing inflammatory serum biomarker levels, the Functional Status Scale (FSS), the Wong-Baker FACES questionnaire, tracking analgesic consumption, and other assessments.

    Sites
    1
    Target
    20
    Study sites
    Atlanta, US

    Sponsor: Emory University

    View on ClinicalTrials.gov(opens in a new tab)
  3. RecruitingPhase 1, Phase 2InterventionalNCT04774536

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Sickle Cell Disease

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    Sites
    3
    Target
    9
    Study sites
    Davis, US +2 more

    Sponsor: Mark Walters, MD

    View on ClinicalTrials.gov(opens in a new tab)
  4. RecruitingObservationalNCT06301893

    Uganda Sickle Surveillance Study (US-3)

    Sickle Cell Disease

    It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data describing the magnitude of the sickle cell problem are lacking in most African countries. The available data on prevalence were mainly from older studies and small numbers of hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80% die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's 111 districts and used a small convenience sample of children aged 6 - 60 months. The objective of this study is to determine the prevalence and map out the burden of SCT and SCD in Uganda.

    Sites
    4
    Target
    1,000,000
    Study sites
    Kampala, UG +3 more

    Sponsor: Children's Hospital Medical Center, Cincinnati

    View on ClinicalTrials.gov(opens in a new tab)
  5. RecruitingObservationalNCT07356050

    Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

    Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia

    The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

    Sites
    3
    Target
    130
    Study sites
    Cincinnati, US +2 more

    Sponsor: Children's Hospital Medical Center, Cincinnati

    View on ClinicalTrials.gov(opens in a new tab)
  6. RecruitingInterventionalNCT06773715

    Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

    Sickle Cell Disease, Vaso-occlusive Pain Episodes

    The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are: Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis? Does virtual reality decrease the daily use of opiates? Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain. All patients will: \- Be asked to fill out a pain assessment survey three times daily for up to 3 days If randomized to intervention arm, patients will: * Participate in an immersive virtual reality experience once daily for up to 3 days * Fill out a survey twice daily to monitor for side effects from virtual reality experience * Fill out a satisfaction survey once during the study period

    Sites
    1
    Target
    36
    Study sites
    New Orleans, US

    Sponsor: Louisiana State University Health Sciences Center in New Orleans

    View on ClinicalTrials.gov(opens in a new tab)
  7. RecruitingInterventionalNCT06184126

    Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

    Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Acute Pain

    This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

    Sites
    1
    Target
    30
    Study sites
    Baltimore, US

    Sponsor: University of Maryland, Baltimore

    View on ClinicalTrials.gov(opens in a new tab)
  8. RecruitingInterventionalNCT07674277

    Virtual Reality for SCD VOC

    Sickle Cell Disease

    This randomized pilot study will evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality (VR) interventions for adults with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC) treated in an infusion center. Up to 50 participants will be enrolled, provide informed consent, and undergo randomization during routine outpatient sickle cell clinic visits when they are clinically stable and not experiencing an acute VOC. Using a randomized, two-period crossover design, each participant will be assigned to receive two of three headset-based interventions during separate qualifying infusion center visits for vaso-occlusive pain occurring within six months of enrollment: sham 2D headset control, passive immersive 3D VR, or active immersive interactive 3D VR. Each intervention will be delivered during a 45-minute session as an adjunct to usual clinical care. The primary outcome is pain burden during the first 60 minutes after intervention start, measured as the area under the curve of 0-10 numeric rating scale pain scores. Secondary outcomes include feasibility of intervention delivery, headset tolerability, pain at 120 minutes, opioid consumption, and participant-reported immersion and acceptability. Findings will inform the design of future trials evaluating VR as an adjunctive treatment for acute vaso-occlusive pain.

    Sites
    1
    Target
    50
    Study sites
    Baltimore, US

    Sponsor: University of Maryland, Baltimore

    View on ClinicalTrials.gov(opens in a new tab)